Z Contains A Cyclopentyl Or Cyclopentene Ring Patents (Class 514/530)
-
Patent number: 6596765Abstract: 15-keto latanoprost and other 15-keto prostaglandin analogs are used as ocularly applied intraocular pressure reducing agents.Type: GrantFiled: May 9, 2001Date of Patent: July 22, 2003Assignee: Sucampo AGInventor: Ryuji Ueno
-
Publication number: 20030130333Abstract: A pharmaceutical composition is disclosed which is comprised of an E-type prostaglandin ligand and a COX-2 selective inhibiting compound, in combination with a pharmaceutically acceptable carrier.Type: ApplicationFiled: April 26, 2002Publication date: July 10, 2003Inventors: Chi Chung Chan, Marc Labelle, Kathleen Metters
-
Patent number: 6589990Abstract: Therapeutic formulations and methods for treating erectile dysfunction with a misoprostol compound in a subject are provided, a method comprising: obtaining a therapeutic formulation having an effective dose of a misoprostol compound in an excipient carrier; and applying the therapeutic formulation topically to the subject.Type: GrantFiled: February 2, 2000Date of Patent: July 8, 2003Inventors: Panagiotis Kanakaris, Petros Karouzakis
-
Publication number: 20030125382Abstract: The present invention relates to a composition of topical preparation containing alprostadil alkyl ester, and more particularly, comprising an alprostadil alkyl ester, an oily vehicle, a skin permeation enhancer and an anti-irritant agent.Type: ApplicationFiled: December 20, 2001Publication date: July 3, 2003Applicant: WHAN IN PHARM. CO., LTD.Inventors: Dong Soo Lee, Kye Kwan Lee, Yun Seok Rhee, Jun Hee Jang, Sun Oh Jeoung, Sang Jin Kim, Sang Cheol Chi
-
Patent number: 6586469Abstract: Tannate compositions consisting of carbetapentane tannate and pyrilamine tannate, which are effective when administered orally for the symptomatic relief of coryza associated with the common cold, sinusitis, allergic rhinitis, unproductive cough and upper respiratory tract conditions, are disclosed.Type: GrantFiled: October 26, 2001Date of Patent: July 1, 2003Assignee: Medpointe Healthcare Inc.Inventor: Steven A. Gordziel
-
Patent number: 6586463Abstract: Compounds having the general structure: which are useful for the treatment of a variety of diseases and conditions, such as bone disorders.Type: GrantFiled: September 4, 2001Date of Patent: July 1, 2003Assignee: The Procter & Gamble CompanyInventors: Mitchell Anthony deLong, David Lindsey Soper, John August Wos, Biswanath De
-
Patent number: 6586468Abstract: A &ohgr;-substituted phenyl-prostaglandin of formula (I), a process for the preparation thereof, a mediciament comprising it as active ingredient (all symbols have the same meaning as described in the specification). The compounds of the formula (I) bind strongly in PGE2 receptor (especially subtype EP4) and therefore are useful for the prophylaxis and/or treatment of immune diseases (autoimmune diseases (amyotrophic lateral sclerosis (ALS) etc.), post-transplantation graft rejection, etc.), asthma, abnormal bone formation, neurocyte death, pulmopathy, hepatopathy, etc. They are also related to sleeping disorders and platelet coagulations, and therefore they are also applicable to these diseases.Type: GrantFiled: June 11, 2001Date of Patent: July 1, 2003Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Toru Maruyama, Shuichi Ohuchida
-
Patent number: 6576663Abstract: Compositions and methods for the treatment of dry eye and related diseases utilizing 6-keto-PGF1&agr; and its analogs are disclosed.Type: GrantFiled: March 23, 2001Date of Patent: June 10, 2003Assignee: Alcon, Inc.Inventor: Peter G. Klimko
-
Publication number: 20030105145Abstract: Polysubstituted indan-1-ol compounds, methods for their preparation; and methods for their use are disclosed herein.Type: ApplicationFiled: August 30, 2002Publication date: June 5, 2003Inventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
-
Patent number: 6569900Abstract: Fulvic acid salts, esters or derivatives thereof in pharmaceutical preparations are effective for treating inflammation, acne, exzema or bacterial or fungal or viral infections. These pharmaceutical preparations may be given either orally or topically in the form of a solution, paste, ointment, powder to humans or animals.Type: GrantFiled: July 9, 2001Date of Patent: May 27, 2003Assignee: Enerkom (Proprietary) LimitedInventors: Johannes Dekker, Constance Elizabeth Medlen
-
Patent number: 6566400Abstract: Cyclic amino acids, such as gabapentin and pregabalin, are used for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants and other addictive drugs/substances. Physiological conditions include stimulant-induced toxicities.Type: GrantFiled: August 29, 2000Date of Patent: May 20, 2003Assignee: Pfizer Inc.Inventors: Hyacinth Chi Akunne, Ann Elizabeth Corbin, David James Dooley, Alysia Latrese Green, Thomas Gary Heffner
-
Patent number: 6566396Abstract: Tannate compositions consisting essentially of carbetapentane tannate and chlorpheniramine tannate which are effective when administered orally for the symptomatic relief of coryza associated with the common cold, sinusitis, allergic rhinitis, unproductive cough and upper respiratory tract conditions are disclosed.Type: GrantFiled: November 30, 2000Date of Patent: May 20, 2003Assignee: Medpointe Healthcare Inc.Inventors: Ronald J. Leflein, Alexander D. D'Addio
-
Patent number: 6566398Abstract: Disclosed is a method for treatment of external secretion disorders, which comprises administering a fatty acid derivative to a subject in need of said treatment. The method of the present invention is useful for treatment of at least one condition selected from hypolacrimation including disorder of basal tear secretion, dry-eye syndrome, hyposalivation and dry-mouth syndrome.Type: GrantFiled: July 13, 2000Date of Patent: May 20, 2003Assignee: R-Tech Ueno, Ltd.Inventor: Ryuji Ueno
-
Patent number: 6562868Abstract: A selective EP2 or EP4 prostanoid receptor agonist can be used to treat female sexual dysfunction. Salts and esters of the agonists can also be used. Formulations comprising such agonists, salts, or esters can be in the form of a cream, gel, ointment, or solid, useful for topical administration.Type: GrantFiled: June 28, 2001Date of Patent: May 13, 2003Assignee: Synphora ABInventors: Johan Stjernschantz, Bahram Resul
-
Publication number: 20030083375Abstract: Methods and compositions for the antagonism of FP receptor-mediated biological responses are disclosed.Type: ApplicationFiled: July 24, 2002Publication date: May 1, 2003Inventors: Najam A. Sharif, Brenda W. Griffin
-
Patent number: 6555577Abstract: The present invention relates to compounds of the general formula (I) The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).Type: GrantFiled: January 26, 2001Date of Patent: April 29, 2003Assignee: Novo Nordisk A/SInventors: John Patrick Mogensen, Per Sauerberg, Paul Stanley Bury, Lone Jeppesen, Ingrid Pettersson
-
Patent number: 6548543Abstract: Remedies or preventives for diseases with a need for immunoregulation, diseases with a need for inhibition of inflammation, diseases with a need for regulation of tumor necrosis factor production, diseases with a need for regulation of fungal growth, diseases with a need for regulation of cell adhesion or disease with a deed for induction of heat-shock protein, which contain as the active ingredient at least one compound selected from among cyclopentenone derivatives represented by general formula [I], optically active isomers and salts thereof, wherein R1 and R2 are the same or different and each represents hydrogen, an aliphatic group, an aromatic group or an aromatic aliphatic group.Type: GrantFiled: February 20, 2001Date of Patent: April 15, 2003Assignee: Takara Shuzo Co., Ltd.Inventors: Eiji Kobayashi, Hiromu Ohnogi, Hiroaki Sagawa, Takanari Tominaga, Eiji Nishiyama, Nobuto Koyama, Katsushige Ikai, Ikunoshin Kato
-
Patent number: 6545045Abstract: This application relates to compositions and methods for the treatment of glaucoma and/or ocular hypertension in mammals utilizing prostaglandin E receptor agonists.Type: GrantFiled: February 4, 2000Date of Patent: April 8, 2003Assignee: Alcon Manufacturing, Ltd.Inventors: Peter G. Klimko, Najam A. Sharif, Brenda W. Griffin
-
Publication number: 20030060484Abstract: The invention relates to agents which combat the hepatitus A virus, containing only minimal amounts of chlorine-containing and/or chlorine cleaving active ingredients, or none of said substances. The inventions also relates to the use of these agents and to a method for their production.Type: ApplicationFiled: September 18, 2002Publication date: March 27, 2003Inventors: Friedrich Von Rheinbaben, Holger Biering, Klaus-Peter Bensemir, Sabine Glaeser
-
Patent number: 6538018Abstract: The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I; where in A, B, D, X, Y, Z, R1, R3 and R4 are as defined in the specification.Type: GrantFiled: March 20, 2002Date of Patent: March 25, 2003Assignee: Allergan, Inc.Inventors: Robert M. Burk, Mark Holoboski, Mari F. Posner
-
Patent number: 6534546Abstract: Compounds represented by the general formula (1): (where R1 is SR6 or NR7R8, where R6 is typically an alkyl group having 1-6 carbon atoms, R7 is a hydrogen atom, an alkyl group having 1-6 carbon atoms or a nitro group, and R8 is a hydrogen atom or an alkyl group having 1-6 carbon atoms; R2 and R3 are each typically a hydrogen atom or an alkyl group having 1-6 carbon atoms; R4 is a hydrogen atom, an alkyl group having 1-6 carbon atoms or an amidino group of which the amine portion may be substituted by an alkyl or nitro group; R5 is a hydrogen atom or an alkyl group having 1-6 carbon atoms; Y1, Y2, Y3 and Y4 which may be the same or different are each typically a hydrogen atom, a halogen atom or an alkoxy group having 1-6 carbon atoms; n and m are each an integer of 0 or 1), or possible stereoisomers or optically active forms of the compounds or pharmaceutically acceptable salts thereof.Type: GrantFiled: June 6, 1997Date of Patent: March 18, 2003Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Toshio Honda, Toshihiko Makino, Toshiaki Nagafuji, Yasushi Kitoh, Nobuaki Kimura
-
Patent number: 6531504Abstract: The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I; wherein hatched lines represent the &agr; configuration, a triangle represents the &bgr; configuration and a dotted line represents the presence or absence of a double bond; A and B are CH2; D represents a covalent bond or CH2, O, S or NH; X is CO2R, CONR2, CH2OR, P(O)(OR)2, CONRSO2R SONR2 or Y is O, OH, OCOR2, halogen or cyano; Z is CH2 or a covalent bond; R is H or R2; R1 is H, R2, phenyl, or COR2; R2 is C1-C5 lower alkyl or alkenyl and R3 is benzothienyl, benzofuranyl, naphthyl or substituted derivatives thereof, wherein the substituents maybe selected from the group consisting of C1-C5 alkyl, halogen, CF3, CN, NO2, NR2, CO2R and OR.Type: GrantFiled: May 17, 2001Date of Patent: March 11, 2003Assignee: Allergan, Inc.Inventors: Robert M. Burk, Todd S. Gac
-
Patent number: 6531485Abstract: This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.Type: GrantFiled: December 16, 1999Date of Patent: March 11, 2003Assignee: Pfizer Inc.Inventors: Kimberly O. Cameron, Paul A. DaSilva-Jardine
-
Patent number: 6528543Abstract: Glucokinase activating compounds of the formula wherein R1 and R2 are independently hydrogen, halo, amino, nitro, cyano, sulfonamido, lower alkyl, perfluoro-lower alkyl, lower alkyl thio, perfluoro-lower alkyl thio, lower alkyl sulfonyl, or perfluoro-lower alkyl sulfonyl; R3 is cycloalkyl having from 3 to 7 carbon atoms or lower alkyl having from 2 to 4 carbon atoms; R4 is hydrogen, lower alkyl, lower alkenyl, hydroxy lower alkyl, halo lower alkyl, R5 and R6 are hydrogen or lower alkyl; and n is 0, 1, 2, 3 or 4; or a pharmaceutically acceptable salt thereofType: GrantFiled: March 21, 2000Date of Patent: March 4, 2003Assignee: Hoffman-La Roche Inc.Inventors: Fred Thomas Bizzarro, Wendy Lea Corbett, Antonio Focella, Joseph Francis Grippo, Nancy-Ellen Haynes, George William Holland, Robert Francis Kester, Paige Erin Mahaney, Ramakanth Sarabu
-
Patent number: 6518305Abstract: Disclosed are compounds of the formula: which are useful for inhibiting neuraminidases from disease-causing microorganisms, especially, influenza neuraminidase. Also disclosed are compositions and methods for preventing and treating diseases caused by microorganisms having a neuraminidase, processes for preparing the compounds and synthetic intermediates used in these processes.Type: GrantFiled: October 19, 1999Date of Patent: February 11, 2003Assignee: Abbott LaboratoriesInventors: Clarence J. Maring, Yuanwei Chen, David A. Degoey, Vincent L. Giranda, David J. Grampovnik, Yu Gui Gu, Warren M. Kati, Dale J. Kempf, April Kennedy, Allan C. Krueger, Zhen Lin, Darold L. Madigan, Steven W. Muchmore, Hing L. Sham, Kent D. Stewart, Vincent S. Stoll, Minghua Sun, Gary T. Wang, Sheldon Wang, Ming C. Yeung, Chen Zhao
-
Publication number: 20030008895Abstract: This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.Type: ApplicationFiled: December 16, 1999Publication date: January 9, 2003Inventors: KIMBERLY O CAMERON, PAUL A. DASILVA-JARDINE
-
Patent number: 6495604Abstract: The present invention provides a compound represented by the formula: wherein R represents an aliphatic hydrocarbon group optionally having substituents, an aromatic hydrocarbon group optionally having substituents, a heterocyclic group optionally having substituents, a group represented by the formula: OR1 (wherein R1 represents a hydrogen atom or an aliphatic hydrocarbon group optionally having substituents) or a group represented by the formula: wherein R1b represents a hydrogen atom or an aliphatic hydrocarbon group optionally having substituents, R1c is, same with or different from R1b, a hydrogen atom or an aliphatic hydrocarbon group optionally having substituents, R0 represents a hydrogen atom or an aliphatic hydrocarbon group, or R and R0 represents a bond with each other, Ar represents an aromatic hydrocarbon group optionally having substituents, and n is an integer of 1 to 4, or a salt thereof, which is a agent for preventing or treating diseaseType: GrantFiled: August 14, 2000Date of Patent: December 17, 2002Assignee: Takeda Chemical Industries, Ltd.Inventors: Yuzo Ichimori, Masayuki Ii, Katsumi Itoh, Tomoyuki Kitazaki, Junji Yamada
-
Publication number: 20020187961Abstract: The invention relates to the use of derivatives of E-type prostaglandins as EP2 agonists, in general, and, in particular as ocular hypotensives.Type: ApplicationFiled: May 24, 2002Publication date: December 12, 2002Inventors: Robert M. Burk, Mark Holoboski, Mari F. Posner
-
Patent number: 6492417Abstract: Methods and compositions for the antagonism of FP receptor-mediated biological responses are disclosed.Type: GrantFiled: December 14, 1998Date of Patent: December 10, 2002Assignee: Alcon Manufacturing, Ltd.Inventors: Najam A. Sharif, Brenda W. Griffin
-
Publication number: 20020173470Abstract: A pharmaceutical composition useful for the treatment of cancer in mammals, comprising as the active ingredient a therapeutically effective amount of a jasmonate of the formula: 1Type: ApplicationFiled: April 4, 2001Publication date: November 21, 2002Inventors: Eliezer Flescher, Orit Fingrut
-
Publication number: 20020169164Abstract: Tricyclic sulfonamide compounds and derivatives are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as inhibitors of matrix metalloproteinases, particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurysm, heart failure, left ventricular dilation, restenosis, periodontal disease, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes or other activated migrating cells, acute and chronic neurodegenerative disorders including stroke, head trauma, spinal cord injury, Alzheimer's disease, amyotrophic lateral sclerosis, cerebral amyloid angiopathy, AIDS, Parkinson's disease, Huntington's disease, prion diseases, myasthenia gravis, and Duchenne's muscular dystrophy.Type: ApplicationFiled: March 27, 2002Publication date: November 14, 2002Applicant: Warner-Lambert CompanyInventors: Patrick Michael O'Brien, Joseph Armand Picard, Drago Robert Sliskovic
-
Patent number: 6469062Abstract: Disclosed is a method for promoting bile secretion, which comprises administering an effective amount of a certain 15-keto-prostaglandin compound to a subject having a disease or condition associated with bile secretion deficient. Also disclosed is a method for treatment of a liver to be transplanted in a liver transplantation process, which comprises contacting the liver with a liquid composition comprising the 15-keto-prostaglandin compound as above.Type: GrantFiled: April 6, 2001Date of Patent: October 22, 2002Assignee: Sucampo A.G.Inventors: Ryuji Ueno, Makoto Suematsu
-
Patent number: 6469061Abstract: A pharmaceutical composition useful for the treatment of cancer in mamnmals, comprising as the active ingredient a therapeutically effective amount of a jasmonate of the formula: wherein: n is 0,1, or 2; R1 is OH, alkoxy, O-glucosyl, or imino; R2 is OH, O, alkoxy or O-glucosyl; R3, R4 and R5 are H, OH, alkoxy or O-glucosyl; and/or wherein R1 and R2, or R1 and R4 together form a lactone; and further wherein the bonds between C3:C7, C4:C5, and C9:C10 may be double or single bonds; or a derivative of said formula; the derivative having at least one of the following: a lower acyl side chain at C3 (free acid, ester or conjugate); a keto or hydroxy (free hydroxy or ester) moiety at the C6 carbon; or an n-pentenyl or n-pentyl side chain at C7. These jasmonates are useful in treating a wide variety of malignancies.Type: GrantFiled: April 4, 2001Date of Patent: October 22, 2002Assignee: Ramot University Authority for Applied Research and Industrial Development LimitedInventors: Eliezer Flescher, Orit Fingrut
-
Publication number: 20020151587Abstract: 15-fluoro substituted analogs of PGF2&agr; and methods of their use in treating glaucoma and ocular hypertension are disclosed.Type: ApplicationFiled: March 18, 2002Publication date: October 17, 2002Inventors: Peter G. Klimko, Mark R. Hellberg, Paul W. Zinke
-
Patent number: 6462081Abstract: The present invention relates to 5-thia-&ohgr;-substituted phenylprostaglandin E derivatives of the formula (I) (wherein, all the symbols are as defined in the specification), process for producing them and pharmaceutical compositions comprising them as active ingredient. The compounds of the formula (I) can bind to PGE2 receptors (especially, subtype EP4) strongly, so they are expected to be useful for prevention and/or treatment of immunological diseases (autoimmune diseases such as amyotrophic lateral sclerosis (ALS), multiple sclerosis, Sjoegren's syndrome, chronic rheumarthrosis and systemic lupus erythematosus etc., and rejection after organ transplantation etc.Type: GrantFiled: December 29, 2000Date of Patent: October 8, 2002Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Toru Maruyama, Shuichi Ohuchida
-
Patent number: 6462080Abstract: The present invention relates to use of prostaglandin E receptor agonists and partial agonists to stimulate mucin secretion to treat dry eye, keratoconjunctivitis, Sjogren's syndrome and related ocular surface diseases.Type: GrantFiled: January 12, 2000Date of Patent: October 8, 2002Assignee: Alcon Manufacturing, Ltd.Inventor: Peter G. Klimko
-
Patent number: 6462082Abstract: The use of HETE derivatives in intraocular surgery (e.g., cataract surgery) is disclosed. The HETE derivatives protect and maintain the corneal endothelium.Type: GrantFiled: September 27, 2001Date of Patent: October 8, 2002Assignee: Alcon Universal Ltd.Inventors: Mutlu Karakelle, Kwan Chan
-
Publication number: 20020143054Abstract: The invention relates to 7-[5-hydroxy-2-(hydroxyhydrocarbyl or heteroatom-substituted hydroxy hydrocarbyl)-3-hydroxy-cyclopentyl(enyl)] heptanoic or heptenoic acids and derivatives of said acids, wherein one or more of said hydroxy groups are replaced by an ether group. The compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma.Type: ApplicationFiled: February 28, 2002Publication date: October 3, 2002Applicant: ALLERGAN, INC.Inventor: Robert M. Burk
-
Patent number: 6458836Abstract: Disclosed is treatment of ocular hypertension and glaucoma by long-term therapy with a prostaglandin related compound for eliminating or reducing potential iridic pigmentation. Composition useful for the treatment, and use of the prostaglandin related compound for producing the composition are also disclosed.Type: GrantFiled: July 9, 2001Date of Patent: October 1, 2002Assignee: Sucampo, A.G.Inventor: Ryuji Ueno
-
Publication number: 20020137793Abstract: The invention relates to compositions and methods for the treatment of dry eye and related diseases utilizing 6-keto-PGF1&agr; and its analogs, according to formula (I); wherein A,B,D,Q9, Q11, R1, X and Y have the meanings given in the description. Some of these compounds are novel.Type: ApplicationFiled: March 23, 2001Publication date: September 26, 2002Inventor: Peter G. Klimko
-
Patent number: 6455727Abstract: The invention pertains to a process for preparing carbetapentane tannate. The process involves the steps of heating carbetapentane to a temperature of about 80 to about 120° C. and slowly adding tannic acid to the carbetapentane while agitating the reaction mixture. Preferably, no water or any other solvent or diluent is utilized in the process.Type: GrantFiled: December 14, 2001Date of Patent: September 24, 2002Assignee: Jame Fine Chemicals, Inc.Inventors: Vilas M. Chopdekar, James R. Schleck, Hemant S. Desai
-
Patent number: 6455584Abstract: To provide a prostaglandin derivative represented by the formula: wherein A is an ethylene group, a vinylene group, an ethynylene group, O(CH2)q or S(O)r(CH2)q, R1 is a C3-10 cycloalkyl group, a C1-4 alkyl-C3-10 cycloalkyl group, a C3-10 cycloalkyl-C1-4 alkyl group, a C1-10 alkyl group, a C1-10 alkyl group substituted with hydroxyl group(s) or C1-4 alkoxy group(s), a C2-10 alkenyl group, a C2-10 alkenyl group substituted with hydroxyl group(s) or C1-4 alkoxy group(s), a C2-10 alkynyl group, a C2-10 alkynyl group substituted with hydroxyl group(s) or C1-4 alkoxy group(s) or a bridged cyclic hydrocarbon group, R2 is a hydrogen atom, a C1-10 alkyl group or a C3-10 cycloalkyl group, m is an integer of 1 to 5, n is an integer of 1 to 4, p is 0, 1 or 2, q is an integer of 1 to 5 and r is 0, 1 or 2; a pharmaceutically acceptable salt thereof or a hydrate thereof exhibit excellent action in inhibiting the growth of vascular smooth muscle and is useful as a drug for inhibition of restenosis after perType: GrantFiled: January 4, 2002Date of Patent: September 24, 2002Assignees: Taisho Pharmaceutical Co., Ltd.Inventors: Fumie Sato, Tohru Tanami, Hideo Tanaka, Naoya Ono, Makoto Yagi, Hitomi Hirano
-
Patent number: 6451859Abstract: Compounds having a structure according to the following formula: are effective in treating disorders such as bone disorders and glaucoma in a subject in need thereof.Type: GrantFiled: August 29, 2001Date of Patent: September 17, 2002Assignee: The Procter & Gamble CompanyInventors: Mitchell Anthony deLong, David Lindsey Soper, John August Wos, Biswanath De
-
Publication number: 20020128313Abstract: A method for reducing the average number of insemination administrations per herd comprising the step of administering to the herd native or extended semen with a simultaneous or sequential administration of prostaglandin is provided. Also provided is a novel composition of matter which includes either native semen, extended semen or a semen extender, one or more prostaglandins and one or more antibioitics.Type: ApplicationFiled: July 3, 2001Publication date: September 12, 2002Inventors: Eric J. Schmitt, James R. Bradford
-
Publication number: 20020128314Abstract: Administration of a pharmaceutical composition in the form of a suppository comprising:Type: ApplicationFiled: May 3, 2002Publication date: September 12, 2002Inventor: Gary W. Neal
-
Publication number: 20020122822Abstract: The invention relates to a process for preparing a soft tablet capable of being chewed or disintegrated in the oral cavity. The tablet is prepared by forming a tablet having a friability of less than about 2% from a mixture comprising a pharmaceutically active ingredient, an excipient in the form of a hydrate, and a water-swellable excipient, and then applying sufficient energy, preferably in the form of heat, to the tablet for a sufficient time to decrease the hardness of the tablet by at least about 20%.Type: ApplicationFiled: December 29, 2000Publication date: September 5, 2002Inventors: Frank J. Bunick, Joseph Luber
-
Publication number: 20020122823Abstract: The invention relates to a tablet capable of being chewed or disintegrated in the oral cavity, which comprises a pharmaceutically active ingredient, and a matrix comprising directly compressible dextrose monohydrate and sucralose, said tablet being substantially fat free and said matrix being substantially free of non-saccharide, water soluble polymeric binders.Type: ApplicationFiled: December 29, 2000Publication date: September 5, 2002Inventors: Frank J. Bunick, Joseph Luber
-
Patent number: 6444840Abstract: The invention provides novel prostaglandin analogs. In particular, the present invention relates to compounds having a structure according to formula (I) wherein R1, R2, R3, R4, R5, R6, W, X, Z, a, b, p and q are defined below. This invention also includes optical isomers, diastereomers and enantiomers of formula (I), and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof. The compounds of the present invention are useful for the treatment of a variety of diseases and conditions, such as bone disorders and glaucoma. Accordingly, the invention further provides pharmaceutical compositions comprising these compounds. The invention still further provides methods of treatment for bone disorders and glaucoma using these compounds or the compositions containing them.Type: GrantFiled: September 28, 2000Date of Patent: September 3, 2002Assignee: The Procter & Gamble Co.Inventors: Mitchell Anthony deLong, Jack Snyder Amburgey, Jr., John August Wos, Biswanath De, David Lindsey Soper
-
Publication number: 20020120006Abstract: Methods and compositions for treating various disorders by administering a therapeutically effective amount of a retinoic acid receptor antagonist alone or in combination or in conjunction with other therapeutic agents to promote angiogenesis are provided. Also provided are methods for obtaining additional retinoic acid receptor antagonists for use as therapeutic agents to promote angiogenesis.Type: ApplicationFiled: September 13, 2001Publication date: August 29, 2002Inventors: Violetta Iotzova, Peter Reczek
-
Patent number: 6441033Abstract: Methods and compositions for the antagonism of FP receptor-mediated biological responses are disclosed.Type: GrantFiled: December 14, 1998Date of Patent: August 27, 2002Assignee: Alcon Manufacturing, Ltd.Inventors: Najam A. Sharif, Brenda W. Griffin